Delving into the Latest Updates on Human papillomavirus vaccine TH-GW (Japan Vaccine/Xenova) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

Genital warts vaccine Japan Vaccine/Xenova, Human papillomavirus vaccine TAGW Japan vaccine/Xenova, TAGW

+ [1]

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication-

Inactive Indication

Human Papillomavirus Infection

Originator Organization

Xenova Group Plc

Active Organization-

Inactive Organization

Xenova Group Plc

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

A phase I double-blind, randomized, placebo-controlled study was carried out in healthy subjects to assess the safety and immunogenicity of TA-GW, a recombinant HPV6 L2E7 fusion protein vaccine for the treatment of genital warts. Forty-two healthy male volunteers were randomised to receive three intramuscular injections of either 0, 3, 30 or 300 microg of recombinant L2E7 adsorbed onto Alhydrogel. Two vaccination schedules were compared: weeks 0, 1 and 4 (accelerated schedule) and weeks 0, 4 and 8 (classical schedule). Subjects were monitored for adverse events throughout. Immunogenicity was assessed by measuring L2E7 specific in vitro T cell proliferative responses, production of IFNgamma and IL-5 and serum antibodies. Dose-dependent and long-lived T and B cell immune responses were elicited by TA-GW with both vaccination schedules. In conclusion, TA-GW is both safe, well-tolerated and immunogenic. The results allow the selection of the 300-microg vaccine formulation and accelerated vaccination schedule for phase II trials in patients with genital warts.

100 Deals associated with Human papillomavirus vaccine TH-GW (Japan Vaccine/Xenova)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Human Papillomavirus Infection	Phase 2	New Zealand	Xenova Group Plc	-
Human Papillomavirus Infection	Phase 2	Canada	Xenova Group Plc	-
Human Papillomavirus Infection	Phase 2	Australia	Xenova Group Plc	-
Human Papillomavirus Infection	Phase 2	United Kingdom	Xenova Group Plc	-